Systemic therapy of disseminated malignant melanoma: an evidence‐based overview of the state‐of‐the‐art in daily routine

Abstract

Although the therapeutic efficacy is very limited, dacarbazine cannot be rejected as standard therapy for disseminated melanoma, because no other therapeutic regimen exhibits a survival benefit over DTIC in an evidence-based analysis. This lack of therapeutic progress over the past 40 years clearly calls for further clinical studies, and patients should be enrolled into clinical trials whenever possible.

Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma

“…Following guidelines [29,[32][33][34][35][36], the type, the dosages and the schemes are still trial-based. Modelling them would have induced the additional higher trial-based costs and biases due the choice of the therapy.…”

“…However, the vast majority of responses are only partial and the median response duration is only four to six months. [29,[32][33][34][35][36].…”

Melanoma primário de mucosa do trato nasossinusal: relato de 18 pacientes e análise de 1077 pacientes na literatura

“…Management of disseminated melanoma is a challenge because of a paucity of effective systemic treatment. 50 In an effort to improve systemic disease control and survival, adjuvant and palliative chemotherapy has been widely used. 3 Dacarbazine monochemotherapy with a single dose of 850-1000 mg/m 2 or a multiple dose regimen of 250 mg/m 2 for 5 days per cycle is currently considered the standard first-line treatment in patients with advanced malignant melanoma.…”

Oral metronomic cyclophosphamide in elderly with metastatic melanoma

“…Metastatic melanoma (MM) has a poor prognosis. Under dacarbazine-based regimen, the median overall survival ranges from 6 to 9 months [2]. Many regimens of mono-chemotherapy, poly-chemotherapy, immunotherapy and bio-chemotherapy have been proposed, but none of these has significantly improved the outcome in such population [3].…”